Effect of iron sucrose on human peritoneal mesothelial cells

European Journal of Clinical Investigation

Volumn 33, Issue 12, 2003, Pages 1038-1044

  Breborowicz M ^a   Polubinska, A ^a   Tam, P ^b   Wu, G ^b   Breborowicz A ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Institute of Kidney Lifescience Technologies   (Canada)

Author keywords

Biocompatibility; Free radicals; Iron sucrose; Mesothelial cells

Indexed keywords

FERRIC HYDROXIDE SUCROSE; INTERLEUKIN 6; LACTATE DEHYDROGENASE; OXYGEN RADICAL;

ARTICLE; BIOCOMPATIBILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; IRON DEFICIENCY ANEMIA; IRON THERAPY; KIDNEY FAILURE; MESOTHELIUM CELL; PERITONEUM CELL; PRIORITY JOURNAL;

CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; DIALYSIS SOLUTIONS; DRUG INTERACTIONS; EPITHELIAL CELLS; FERRIC COMPOUNDS; FREE RADICALS; HUMANS; INTERLEUKIN-6; PERITONEAL CAVITY;

EID: 0348141031     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2003.01264.x     Document Type: Article

References (24)

1. Nissenon AR, Strobos J. Iron deficiency in patients with renal failure. Kidney Int Suppl 1999;99:s18-s21.
2. Tinawi M, Martisn KJ, Bastani B. Oral iron absorption test in patients on CAPD comparison of ferrous sulfate and a polysaccharide ferric complex. Nephron 1996;74:291-4.
3. Kooistra MP, Marx JMM. The absorption of iron is disturbed in recombinant human erythropoietin-treated peritoneal dialysis patients. Nephrol Dial Transplant 1998;13:2578-82.
4. Fishbane S, Ungureanu VD, Maesaka JK, Kaupke CJ, Lim V, Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996;28:529-34.
5. Nissenson AR, Lindsay RM, Swan S, Seligman P, Strobos J. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American clinical trial. Am J Kidney Dis 1999;33:471-82.
6. Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer®) vs. iron gluconate (Ferrlecit®) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant 2001;16:1239-44.
7. Sunder-Plassmann G, Horl WH. Comparative look at intravenous iron agents, pharmacology, efficacy, and safety of iron dextran, iron saccharate, and ferric gluconate. Semin Dial 1999;12:243-8.
8. Fishbane S, Kowalski EA. The comparative safety of intravenous iron dextran, iron saccharate, and sodium gluconate. Semin Dial 2000;13:381-4.
9. Zager RA, Johnson ACM, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002;40:90-103.
10. Suzuki K, Twardowski ZJ, Nolph KD, Khanna R, Moore HL. Absorption of iron dextran from the peritoneal cavity of rats. Adv Perit Dial 1995;11:57-9.
11. Bastani B, Gulley S. Intraperitoneal iron-dextran as a potential route of iron therapy in CAPD patients. Perit Dial Int 1996;16:646-8.
12. Mars RL, Moles K, Pope K, Hargrove P. Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin. Adv Perit Dial 1999;15:60-4.
13. Park SE, Twardowski ZJ, Moore HL, Khanna R, Nolph KD. Chronic administration of iron dextran into the peritoneal cavity in rats. Perit Dial Int 1997;17:179-85.
14. Pecoits-Filho RFS, Twardowski ZJ, Kim YL, Khanna R, Moore H, Nolph KD. The absence of toxicity in intraperitoneal iron dextran administration: a functional and histological analysis. Perit Dial Int 1998;18:64-70.
15. Reddy DK, Moore HL, Lee JH, Saran R, Nolph KD, Khanna R et al. Chronic peritoneal dialysis in iron-deficient rats with solutions containing iron dextran. Kidney Int 2001;59:764-73.
16. Breborowicz A, Rodela H, Oreopoulos DG. Toxicity of osmotic solutes on human mesothelial cells in vitro. Kidney Int 1992;41:1280-5.
17. Macougall IC. Strategies for iron supplementation: oral versus intravenous. Kidney Int 1999;55 (Suppl.):s61-s66.
18. Vychytil A, Haag-Weber M. Iron status and iron supplementation in peritoneal dialysis patients. Kidney Int 1999;55 (Suppl.):s71-s78.
19. Rooyakkers TM, Stroes ESG, Kooista MP, van Faassen EE, Hider RC, Rabelink TJ et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002;32 (Suppl. I):9-16.
20. Gotloib L, Shostack A, Ber Sella P, Cahen R. Continuous mesothelial injury and regeneration during long term peritoneal dialysis. Perit Dial Bull 1987;7:148-55.
21. Ghio AJ, Kennedy TP, Stonehuerner J, Carter JD, Skinner KA, Parks DA et al. Iron regulates xanthine oxidase activity in the lung. Am J Physiol Lung Cell Mol Physiol 2002; 283:L563-L572.
22. Balla JV, Yachie A, Varga Z, Vercellotti GM, Eaton JW, Balla G. Pro-oxidant and cytotoxic effects of circulating heme. Blood 2002;100:879-87.
23. Stenvinkel P, Barany P. Anemia rHuEPO resistance, and cardiovascular disease in end-stage renal failure; links to inflammation and oxidative stress. Nephrol Dial Transplant 2002;17 (Suppl. 5):32-7.
24. Okada S, Hamazaki S, Toyokuni S, Midorikawa O. Induction of mesothelioma by intraperitoneal injections of ferric saccharate in male Wistar rats. Br J Cancer 1989;60:708-11.